Talis Biomedical Valuation Multiples

Talis Biomedical is valued at $5M, a 12.6x revenue multiple. In the last fiscal year, Talis Biomedical revenue was $412K and Talis Biomedical EBITDA was ($61M).

Talis Biomedical Overview

About Talis Biomedical

Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.


Founded

2013

HQ

United States

Employees

99

Financials (Last FY)

Revenue: $412K
EBITDA: ($61M)

EV

$5M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Talis Biomedical Financials

Talis Biomedical reported last fiscal year revenue of $412K and negative EBITDA of ($61M).

In the same fiscal year, Talis Biomedical generated $371K in gross profit, ($61M) in EBITDA losses, and had net loss of ($62M).


Talis Biomedical P&L

In the most recent fiscal year, Talis Biomedical reported revenue of $412K and EBITDA of ($61M).

Talis Biomedical is unprofitable as of last fiscal year, with gross margin of 90%, EBITDA margin of (14863%), and net margin of (15050%).

See analyst estimates for Talis Biomedical
Last FY2023202620272028
Revenue$412K$412K
Gross Profit$371K$371K
Gross Margin90%90%
EBITDA($61M)($61M)
EBITDA Margin(14863%)(14863%)
EBIT Margin(16217%)(16217%)
Net Profit($62M)($62M)
Net Margin(15050%)(15050%)
Net Debt($57M)-

Financial data powered by Morningstar, Inc.

Talis Biomedical Stock Performance

Talis Biomedical has current market cap of $5M, and enterprise value of $5M.

EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$5M$5M-----

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Talis Biomedical Valuation Multiples

Talis Biomedical trades at 12.6x EV/Revenue multiple, and (0.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Talis Biomedical

Talis Biomedical Financial Valuation Multiples

As of November 21, 2026, Talis Biomedical has market cap of $5M and EV of $5M.

Talis Biomedical has a P/E ratio of (0.1x).

Last FY2023202620272028
EV/Revenue12.6x12.6x
EV/EBITDA(0.1x)(0.1x)
EV/EBIT(0.1x)(0.1x)
EV/Gross Profit14.0x14.0x
P/E(0.1x)(0.1x)
EV/FCF(0.1x)(0.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Talis Biomedical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Talis Biomedical Margins & Growth Rates

In the most recent fiscal year, Talis Biomedical reported gross margin of 90%, EBITDA margin of (14863%), and net margin of (15050%).

See estimated margins and future growth rates for Talis Biomedical

Talis Biomedical Margins

Last FY202720282029
Gross Margin90%
EBITDA Margin(14863%)
EBIT Margin(16217%)
Net Margin(15050%)
FCF Margin(13040%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Talis Biomedical Operational KPIs

Talis Biomedical's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.

Access forward-looking KPIs for Talis Biomedical
Last FY2023202620272028
Revenue per Employee$0.0M-
Opex per Employee$0.7M-
R&D Expenses to Revenue9877%9877%
Opex to Revenue16735%16735%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Talis Biomedical Competitors

Talis Biomedical competitors include Proteome Sciences, Zicix, IMD Companies, Euroinvestment, Co-Diagnostics, Amwill Healthcare, Constance Care, Speed Medical SAE, MedNation and Eukedos.

Most Talis Biomedical public comparables operate across Hospitals & Clinics and Laboratory Services.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Proteome Sciences$5M($2M)5.0x-(10.9x)-
Zicix$731K($699K)10.8x-(11.3x)-
IMD Companies------
Euroinvestment-($1K)--(2294.1x)-
Co-Diagnostics$622K($48M)3.6x3.4x(0.0x)-
Amwill Healthcare$5M$1M1.3x-4.7x-
Constance Care-$9K--548.3x-
Speed Medical SAE------

This data is available for Pro users. Sign up to see all Talis Biomedical competitors and their valuation data.

Start Free Trial

Talis Biomedical VC Funding History

Before going public, Talis Biomedical raised $31M in total equity funding, across 2 rounds.


Talis Biomedical Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Mar-15Series B-$27M-SlipChip is a Pasadena-based Caltech spinoff developing microfluidics technology, originating from research in Rustem Ismagilov's lab for applications like portable HIV testing using devices paired with cell phones. The company raised a total of $59.49M across 3 strategic funding rounds, starting with a Series A of $4M on August 8, 2013. A Series B round included $26.5M from six investors as part of an ongoing $30M effort, with further details on the most recent Series B of $28.94M in October 2017 for expansion, product development, and market penetration.
Aug-13Series A-$4M-SlipChip, a Pasadena-based Caltech spinoff, develops microfluidics technology originating from research in Rustem Ismagilov's laboratory at Caltech. The technology enables applications such as determining molecule concentrations in samples using devices paired with a cell phone, including tests for HIV with portable devices. SlipChip completed a Series A funding round of $4M on August 8, 2013. The company raised a total of $59.49M across three strategic funding rounds, with later rounds including a Series B of $28.94M in October 2017 and an ongoing $30M Series B effort with $26.5M raised by six investors. In June 2013, SlipChip LLC merged into SlipChip Corporation, a Delaware corporation.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Talis Biomedical

When was Talis Biomedical founded?Talis Biomedical was founded in 2013.
Where is Talis Biomedical headquartered?Talis Biomedical is headquartered in United States.
How many employees does Talis Biomedical have?As of today, Talis Biomedical has over 99 employees.
Is Talis Biomedical publicly listed?Yes, Talis Biomedical is a public company listed on OTCM.
What is the stock symbol of Talis Biomedical?Talis Biomedical trades under TLIS ticker.
When did Talis Biomedical go public?Talis Biomedical went public in 2021.
Who are competitors of Talis Biomedical?Talis Biomedical main competitors include Proteome Sciences, Zicix, IMD Companies, Euroinvestment, Co-Diagnostics, Amwill Healthcare, Constance Care, Speed Medical SAE, MedNation, Eukedos.
What is the current market cap of Talis Biomedical?Talis Biomedical's current market cap is $5M.
What is the current revenue of Talis Biomedical?Talis Biomedical's last fiscal year revenue is $412K.
What is the current EV/Revenue multiple of Talis Biomedical?Current revenue multiple of Talis Biomedical is 12.6x.
Is Talis Biomedical profitable?No, Talis Biomedical is not profitable.
How many companies Talis Biomedical has acquired to date?Talis Biomedical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Talis Biomedical has invested to date?Talis Biomedical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Talis Biomedical

Lists including Talis Biomedical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial